Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

perienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.  Patients enrolled in the trial had moderate to advanced PD and were not adequately responsive to current therapies.  

"We are very pleased that Dr. Lewitt had the opportunity to provide more information about our study methodology and some further details as to the nature of the improvements seen in patients treated in our Phase 2 study.  We remain confident in our study results, which we feel confirm that NLX-P101 has great potential to offer an important new therapy for patients with Parkinson's disease," said Clark A. Johnson, President and Chief Executive Officer of the Company.  

Mr. Johnson added, "We continue to believe that the best venue for the full disclosure of our Phase 2 results would be in a respected peer-reviewed medical or scientific journal.  All of the major details of our previous pre-clinical and clinical studies have been published in leading journals, including Science, The Lancet and the Proceedings of the National Academy of Sciences.  We believe that the credibility provided by these publications enhance the value of our product and of our company."

Neurologix, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of gene transfer therapies for serious disorders of the brain and central nervous system (CNS).  Neurologix's investigational AAV (adeno-associated virus) vector gene therapy, NLX-P101, is a novel, non-dopaminergic approach that uses an inhibitory gene (glutamic acid decarboxylase or "GAD") to selectively alter the neural circuitry affected in PD and, thereby, normalize brain physiology.  Neurologix's technology is the only gene therapy strategy currently in development which bypasses the dopamine system.  

Neurologix an
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
(Date:7/31/2014)... 31, 2014 Xencor Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the second quarter ended June ... business highlights. "In the second quarter, ... Society 2014 International Conference (ATS) demonstrating three novel ...
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... NEW CENTERS AND TO ... INCREASE AWARENESS AMONG CARDIOLOGISTS, PLEASANTON, Calif., April 21 ... mechanical,circulatory support therapies to save, support and restore failing hearts,said ... (PreMarket,Approval) application, allowing the use of its HeartMate II LVAS ...
... April 21 A new study funded by,Health ... correlation,between dietary consumption of the omega-3 DHA* and ... Universite Laval,researchers and published in the Journal of ... pregnancy boosts an infant,s sensory,cognitive, and motor development., ...
Cached Medicine Technology:Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 2Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 3Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 4Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 5Pregnant Women Need Omega-3 to Boost Infant Development 2
(Date:7/31/2014)... study published today in Genes & Development ... Sciences Centre,s DNA Replication group, in collaboration with ... intricate mechanisms involved in the enzyme that governs ... sophisticated system using synthetic, chemical and structural biology ... involved in duplicating genetic information embraces DNA through ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces the ... simplified and predictable with fixed fees across the board, ... international provider of legal discovery management services for law ... apparent that both the courts and legal counsel alike ... complex pricing structure that plagues the litigation support industry. ...
(Date:7/31/2014)... 2014 The Alaska Center for ... new dentist Dr. Jonathan Oudin, DDS, who will begin ... in Barrow, Alaska, for three years. According to Teresa ... Dr. Oudin to help take on new patients. , ... continue growing and serving the greater Anchorage metro community," ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Transplant surgeons often feel ... for burnout, a new study suggests. Nearly ... reported having a low sense of personal accomplishment ... emotionally exhausted, researchers found. "Burnout is common ... study co-author Dr. Marwan Abouljoud, director of the ...
(Date:7/31/2014)... algorithm aimed to diagnose pediatric patients with suspected ... scans, without affecting diagnostic accuracy, Mayo Clinic Children,s ... published in the journal Surgery . , ... acute abdominal pain in children. Appendicitis occurs when ... CT scans are often used to diagnose acute ...
Breaking Medicine News(10 mins):Health News:Molecular gate that could keep cancer cells locked up 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2
... to more false positives, additional work-ups , , THURSDAY, Jan. ... estimating glomerular filtration (eGFR) rates from routine blood work ... with chronic kidney disease, U.S. researchers report. , The ... kidneys over time, and its formula factors in measures ...
... BETHESDA, Md., Jan. 29 /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: ... of western healthcare,products and services in the People,s Republic ... third quarter 2009 financial results on Monday,February 9, 2009, ... 8:00 am ET that day to discuss financial results. ...
... Meditation technique may help keep discomfort at bay, study ... Zen meditation appears to reduce sensitivity to moderate pain ... "Previous studies had already shown that teaching patients with ... no one had examined how these effects might come ...
... management system designed to meet unique supply management ... Fla., Jan. 29 Omnicell, Inc. (Nasdaq: ... solutions to acute healthcare facilities, and Shands HealthCare ... chain management systems (formerly known as OptiFlex SS) ...
... and FORT LAUDERDALE, Fla., Jan. 29 Houlihan Smith,& ... into Tri-Tech Health, LLC, (Tri-Tech Health) as announced by,Charles ... The,advisory services were led by Houlihan Smith Managing ... , "We have been working ...
... Cholera Outbreak STAMFORD, Conn., Jan. 29 AmeriCares is ... in an effort to stem a deadly cholera outbreak ... outbreak is one of Africa,s deadliest in 15 years ... is at risk. With limited medical resources and dismal ...
Cached Medicine News:Health News:Kidney Function Test May Not Be Cost-Effective 2Health News:Chindex International, Inc. to Report Fiscal Third Quarter 2009 Financial Results 2Health News:The Zen Way to Pain Relief 2Health News:The Zen Way to Pain Relief 3Health News:The Zen Way to Pain Relief 4Health News:Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems 2Health News:Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems 3Health News:Houlihan Smith Arranges Equity Investment Into Tri-Tech Health, LLC 2Health News:AmeriCares Doubles Aid to Zimbabwe 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: